A Multicenter Phase II Trial of mFOLFOX6 Plus Bevacizumab to Treat Liver-Only Metastases of Colorectal Cancer that are Unsuitable for Upfront Resection (TRICC0808)

Annals of Surgical Oncology

Volumn 22, Issue 3, 2015, Pages 908-915

  Uetake, Hiroyuki ^a   Yasuno, Masamichi ^b   Ishiguro, Megumi ^a   Kameoka, Shingo ^c   Shimada, Yasuhiro ^d   Takahashi, Keiichi ^e   Watanabe, Toshiaki ^f   Muro, Kei ^g   Baba, Hideo ^h   Yamamoto, Junji ⁱ   Mizunuma, Nobuyuki ^j   Tamagawa, Hiroshi ^k   Mochizuki, Izumi ^l   Kinugasa, Yusuke ^m   Kikuchi, Takashi ⁿ   Sugihara, Kenichi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN HIROO HOSPITAL   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g AICHI CANCER CENTER HOSPITAL   (Japan)

^h KUMAMOTO UNIVERSITY   (Japan)

ⁱ NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^j CANCER INSTITUTE HOSPITAL   (Japan)

^k OSAKA GENERAL MEDICAL CENTER   (Japan)

^l Iwate Prefectural Central Hospital   (Japan)

^m SHIZUOKA CANCER CENTER   (Japan)

ⁿ Translational Research Informatics Center   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; MONOCLONAL ANTIBODY; OXALIPLATIN; PLATINUM COMPLEX;

ADULT; AGED; CANCER STAGING; CLINICAL TRIAL; COLORECTAL NEOPLASMS; FEMALE; FOLLOW UP; HUMAN; LIVER NEOPLASMS; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROGNOSIS; SECONDARY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS;

EID: 84925488809     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-4094-7     Document Type: Article

References (18)

1. Watanabe T, Itabashi M, Shimada Y, et al. Japanese Society for Cancer of the Colon and Rectum: Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol. 2012;17:1–29.
2. Sugihara K, Uetake H. Therapeutic strategies for hepatic metastasis of colorectal cancer: overview. J Hepatobiliary Pancreat Sci. 2012;19:523–7.
3. Japanese Classification of Colorectal Carcinoma. Japanese society of cancer of the colon and rectum. Tokyo: Kanehara-Shuppan; 2009. p. 11.
4. Kato T, Yasui K, Hirai T, et al. Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum. 2003;46:S22–31.
5. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229–37.
6. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.
7. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–9.
8. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–17.
9. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27:663–71.
10. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28:4697–705.
11. Nordlinger B, Sorbye H, Glimelius B, et al; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007–16.
12. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644–57.
13. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11:38–47.
14. Folprecht G, Gruenberger T, Bechstein W, et al. Cetuximab and chemotherapy in the treatment of patients with initially “non-resectable” colorectal (CRC) liver metastases—long term follow up of the CELIM trial. J Clin Oncol. 2013;31:abstr 3538.
15. Wong R, Cunningham D, Barbachano Y, et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol. 2011;22:2042–8.
16. Garufi C, Torsello A, Tumolo S, et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer. 2010;103:1542–7.
17. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 2006. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf#search=‘Common+Terminology+Criteria+for+Adverse+Events+v3.0+ %28CTCAE %29′. Accessed 14 Nov 2014.
18. Nordlinger B, Van Cutsem E, Gruenberger T, et al; European Colorectal Metastases Treatment Group; Sixth International Colorectal Liver Metastases Workshop. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol. 2009;20:985–92.